Literature DB >> 30007459

Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.

Joseph H Butterfield1, Anupama Ravi2, Thanai Pongdee3.   

Abstract

Mast cells leave evidence, a "fingerprint," of their participation in acute and chronic clinical events. That fingerprint is an elevation, either chronic or acute, in levels of their secreted mediators or their metabolites. Of these, only serum tryptase is currently one of the diagnostic criteria for systemic mastocytosis or mast cell activation. Combinations of easily obtained and quantified urinary mast cell mediator metabolite levels correlate well with bone marrow findings of systemic mastocytosis. By inhibiting synthesis of or blockading receptors to the elevated mast cell mediator, relief of clinical symptoms can often be achieved.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2,3,dinor-11βProstaglandin(PG) F2α; Histamine; Leukotriene(LT) E4; N-methylhistamine; Neuropeptide; Tryptase

Mesh:

Substances:

Year:  2018        PMID: 30007459     DOI: 10.1016/j.iac.2018.04.011

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  7 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

2.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.

Authors:  Hanneke C Kluin-Nelemans; Andreas Reiter; Anja Illerhaus; Bjorn van Anrooij; Karin Hartmann; Lambertus F R Span; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Alexander Zink; David Fuchs; Alex Kilbertus; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Dietger Niederwieser; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Lortholary; Thilo Jakob; Olivier Hermine; Julien Rossignol; Michel Arock; Jason Gotlib; Peter Valent; Wolfgang R Sperr
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

Review 3.  Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence.

Authors:  Dariusz Szukiewicz; Piotr Wojdasiewicz; Mateusz Watroba; Grzegorz Szewczyk
Journal:  J Immunol Res       Date:  2022-06-22       Impact factor: 4.493

4.  Candidalysin, a Virulence Factor of Candida albicans, Stimulates Mast Cells by Mediating Cross-Talk Between Signaling Pathways Activated by the Dectin-1 Receptor and MAPKs.

Authors:  Pu Song; Ge Peng; Hainan Yue; Takasuke Ogawa; Shigaku Ikeda; Ko Okumura; Hideoki Ogawa; François Niyonsaba
Journal:  J Clin Immunol       Date:  2022-04-14       Impact factor: 8.542

Review 5.  Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target.

Authors:  Chiara Agostinis; Andrea Balduit; Alessandro Mangogna; Gabriella Zito; Federico Romano; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

Review 6.  Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.

Authors:  Clayton Webster Jackson; Cristina Marie Pratt; Chase Preston Rupprecht; Debendra Pattanaik; Guha Krishnaswamy
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

7.  Expression of Carboxypeptidase A3 and Tryptase as Markers for Lymph Node Metastasis of Canine Cutaneous Mast Cell Tumors.

Authors:  Tuddow Thaiwong; Juliana V Cirillo; Jane Heller; Matti Kiupel
Journal:  Front Vet Sci       Date:  2022-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.